Rae Lab

Around 70% of breast cancer cases are ER-positive, responding initially to drugs that block ER signaling. Despite this, nearly one-third of newly diagnosed patients face metastatic recurrence, and almost all with metastatic ER-positive cancer become resistant to current anti-estrogen treatments, resulting in disease progression and mortality. 

This highlights an urgent need for more effective therapies to combat drug resistance and improve outcomes for these patients. Emphasizing personalized medicine, the lab addresses drug resistance to improve therapeutic strategies. 

Supported by the Breast Cancer Research Foundation, their collaborative approach aims to advance precision medicine, enhancing treatment options and outcomes for breast cancer patients.